Last reviewed · How we verify
Malignant lymphoma - small lymphocytic
Approved treatments
- Imbruvica · AbbVie
Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells. - Imbruvica · Rabin Medical Center
- Venclexta · AbbVie
Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. - Copiktra · Secura
Copiktra works by blocking an enzyme that helps cancer cells grow and multiply. - Zydelig · University of Maryland, Baltimore
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Malignant lymphoma - small lymphocytic patent landscape — cliff calendar, originator estates, attackable patents
- Malignant lymphoma - small lymphocytic treatment landscape brief
- Malignant lymphoma - small lymphocytic treatment updates RSS
Frequently asked questions about Malignant lymphoma - small lymphocytic
What drugs treat Malignant lymphoma - small lymphocytic?
Tracked treatments include Imbruvica, Venclexta, Copiktra, Zydelig.
What is the treatment for Malignant lymphoma - small lymphocytic?
Standard treatment for Malignant lymphoma - small lymphocytic includes Imbruvica, Venclexta, Copiktra, Zydelig. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Malignant lymphoma - small lymphocytic patent cliff · Malignant lymphoma - small lymphocytic CI report
- Treatment: Imbruvica · AbbVie
- Treatment: Imbruvica · Rabin Medical Center
- Treatment: Venclexta · AbbVie
- Treatment: Copiktra · Secura
- Treatment: Zydelig · University of Maryland, Baltimore
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing